For this reason, when an appropriate donor is available (HLA identical sibling or a matched unrelated), we are keen to always consider alloHSCT in CR1 for NPM1mut, FLT3-ITD positive AML patients, no matter the allele burden of this latter mutation. Here, FLT3 is linked to acute myeloid leukemia.